ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Tevogen Bio Holdings Inc

Tevogen Bio Holdings Inc (TVGN)

0.698
-0.002
(-0.29%)
Closed July 08 4:00PM
0.698
0.00
( 0.00% )
Pre Market: 4:05AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.698
Bid
0.3068
Ask
0.72
Volume
-
0.00 Day's Range 0.00
0.653 52 Week Range 21.09
Market Cap
Previous Close
0.698
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
874,975
Shares Outstanding
166,114,418
Dividend Yield
-
PE Ratio
-1,750.00
Earnings Per Share (EPS)
-0
Revenue
-
Net Profit
-67k

About Tevogen Bio Holdings Inc

Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Tevogen Bio is a leading NextGen clinical-stage specialty immunotherapy Biotech developing off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.

Sector
Biological Pds,ex Diagnstics
Industry
Blank Checks
Headquarters
Wilmington, Delaware, USA
Founded
2024
Tevogen Bio Holdings Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker TVGN. The last closing price for Tevogen Bio was $0.70. Over the last year, Tevogen Bio shares have traded in a share price range of $ 0.653 to $ 21.09.

Tevogen Bio currently has 166,114,418 shares outstanding. The market capitalization of Tevogen Bio is $115.95 million. Tevogen Bio has a price to earnings ratio (PE ratio) of -1750.00.

TVGN Latest News

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (“Tevogen”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

This new registration statement does not relate to any previously undisclosed new issuances of dilutive securities.Includes issuance of shares underlying warrants originally issued in 2021...

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

WARREN, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

Tevogen Bio Set to Join Russell 3000® Index

WARREN, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq:...

CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

WARREN, N.J., June 07, 2024 (GLOBE NEWSWIRE) -- A release was issued under a similar headline on Thursday, June 6th by Tevogen Bio Holdings Inc. (Nasdaq: TVGN). Please note that the second...

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event

WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy company harnessing one of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.002-0.2857142857140.70.75110.653873320.69906746CS
4-0.0983-12.34459374610.79631.110.6532868050.81241761CS
12-1.662-70.42372881362.362.420.6538749750.97204012CS
26-3.402-82.97560975614.121.090.6537298751.74232884CS
52-3.402-82.97560975614.121.090.6537298751.74232884CS
156-3.402-82.97560975614.121.090.6537298751.74232884CS
260-3.402-82.97560975614.121.090.6537298751.74232884CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PEGYPineapple Energy Inc
$ 2.00
(66.67%)
694.05k
SVMHSRIVARU Holding Ltd
$ 0.246
(29.47%)
289.01k
ZAPPZapp Electric Vehicles Group Ltd
$ 11.90
(28.79%)
114.24k
MYNZMainz BioMed NV
$ 0.5899
(23.67%)
418.09k
BTCSBTCS Inc
$ 1.63
(16.43%)
70
NVOSNovo Integrated Sciences Inc
$ 0.605
(-19.87%)
861
SHPWShapeways Holdings Inc
$ 0.4076
(-16.41%)
13.47k
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.60
(-15.78%)
6.7k
HYWHywin Holdings Ltd
$ 0.3323
(-14.77%)
3.33k
JTAIJet AI Inc
$ 0.30
(-9.39%)
1
PEGYPineapple Energy Inc
$ 2.00
(66.67%)
694.05k
MAXNMaxeon Solar Technologies Ltd
$ 0.2835
(5.00%)
626.31k
MYNZMainz BioMed NV
$ 0.5899
(23.67%)
418.09k
SVMHSRIVARU Holding Ltd
$ 0.246
(29.47%)
289.01k
ZAPPZapp Electric Vehicles Group Ltd
$ 11.90
(28.79%)
114.24k

TVGN Discussion

View Posts
ChuckPaul63 ChuckPaul63 2 months ago
Corporate overview: Robust and IMPRESSIVE drug pipeline. (tevogen.com) $TVGN.
👍️ 1
harry crumb harry crumb 2 months ago
Pour souls on this scam
👍️0
glenn1919 glenn1919 2 months ago
TVGN.............................https://stockcharts.com/h-sc/ui?s=TVGN&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 2 months ago
TVGN: Up 52% in the Post-M right now behind last Friday's (Post-M) PR --- behind circa 15-mil. shares Float. Said (Post-Close) Friday news elaborated that they secured $51-mil. financing. Also, some recent April 2024 news about no more circa $91-mil. "liability" to worry about. (Whelp, not exactly a CURE for Cancer, so far, nor any of the many diseases they are targeting; but appears they are getting their MONEY in good order.)
https://www.globenewswire.com/news-release/2024/05/10/2879865/0/en/Tevogen-Bio-Announces-Up-to-50-Million-in-Financing-to-Further-Advance-Operational-Objectives.html (This identical PR was splattered over many, many, news media sites.)
👍️0
tw0122 tw0122 2 months ago
Jump jump
👍️0
Monksdream Monksdream 3 months ago
TVGN SPAC junk new 52 lo

👍️0
2020trader 2020trader 3 months ago
TVGN down 12% today, expecting lower
👍️0
Monksdream Monksdream 3 months ago
SPAC junk
👍️0
2020trader 2020trader 3 months ago
down 17% today
👍️0
2020trader 2020trader 3 months ago
expecting lower
👍️0
Monksdream Monksdream 3 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 3 months ago
Will it grow legs after 9:30
https://ih.advfn.com/markets/nasdaq/premarket
👍️0
Monksdream Monksdream 3 months ago
Tevogen Bio Holdings Inc NASDAQ: TVGN

GoSymbol lookup
Health Care : Biotechnology | Company profile
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
👍️0

Your Recent History

Delayed Upgrade Clock